Carter has been Chief Science Officer at Voyager since 2022. Starting in 2016 and prior to his role as CSO, Carter held roles of increasing responsibility at Voyager, most recently serving as senior vice president of research. He led novel gene therapy development programs and supported the development of the TRACER™ platform, the identification of novel AAV capsids, and the execution of multiple successful industry partnerships. Before joining Voyager, Carter served as the Senior Science Advisor to the Office of the Director of the Broad Institute of MIT and Harvard, where he was the lead scientific advisor and manager for several internal and external science programs, with a focus on moving innovative science concepts toward the clinic. Previously, he led research at BrainCells, Inc. as Senior Director of Biology, including evaluation of novel targets for CNS disease and the pre-clinical to clinical transition of the company’s lead program. Carter received a B.A. in genetics from Texas A&M University, a Ph.D. in genetics from Columbia University, and completed his postdoctoral training at the Salk Institute for Biomedical Research.